KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

Pier Francesco Ferrucci 1, Anna Maria Di Giacomo, Michele Del Vecchio, Victoria Atkinson, Henrik Schmidt, Jacob Schachter, Paola Queirolo 1,7,8, Georgina V Long 9,10, Rosalie Stephens, Inge Marie Svane, Michal Lotem, Mahmoud Abu-Amna, Eduard Gasai, Razi Ghori, Scott J Diede 16, Elizabeth S Croydon, Antoni Ribas, Paolo Antonio Ascierto 18, for the KEYNOTE-022 international team

ABSTRACT

Background In the KEYNOTE-022 study, pembrolizumab with dabrafenib and trametinib (triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and trametinib (doublet) without reaching statistical significance. Mature results on PFS, duration of response (DOR), and overall survival (OS) are reported.

Methods The double-blind, phase 2 part of KEYNOTE-022 enrolled patients with previously untreated BRAF V600E/K-mutated advanced melanoma from 22 sites in seven countries. Patients were randomly assigned 1:1 to intravenous pembrolizumab (200 mg every 3 weeks) or placebo plus dabrafenib (150 mg orally two times per day) and trametinib (2 mg orally one time a day). Primary endpoint was PFS. Secondary endpoints were objective response rate, DOR, and OS. Efficacy was assessed in the intention-to-treat population, and safety was assessed in all patients who received at least one dose of study drug. This analysis was not specified in the protocol.

Results Between November 30, 2015 and April 24, 2017, 120 patients were randomly assigned to triplet (n=60) or doublet (n=60) therapy. With 36.6 months of follow-up, median PFS was 16.9 months (95% CI 11.3 to 27.9) with triplet and 10.7 months (95% CI 7.2 to 16.8) with doublet (HR 0.53; 95% CI 0.34 to 0.83). With triplet and doublet, respectively, PFS at 24 months was 41.0% (95% CI 27.4% to 54.2%) and 16.3% (95% CI 8.1% to 27.1%); median DOR was 25.1 months (95% CI 14.1 to not reached) and 12.1 months (95% CI 6.0 to 15.7), respectively. Median OS was not reached with triplet and was 26.3 months with doublet (HR 0.64; 95% CI 0.38 to 1.06). With triplet and doublet, respectively, OS at 24 months was 63.0% (95% CI 49.4% to 73.9%) and 51.7% (95% CI 38.4% to 63.4%). Grade 3–5 treatment-related adverse events (TRAEs) occurred in 35 patients (58%, including one death) receiving triplet and 15 patients (25%) receiving doublet.

Conclusion In BRAF V600E/K-mutant advanced melanoma, pembrolizumab plus dabrafenib and trametinib substantially improved PFS, DOR, and OS with a higher incidence of TRAEs. Interpretation of these results is limited by the post hoc nature of the analysis.

INTRODUCTION

Immunotherapies with antiprogrammed death 1 (PD-1) monoclonal antibodies, either alone or in combination with anticytotoxic T-lymphocyte-associated antigen 4 monoclonal antibodies, and targeted therapies with BRAF plus MEK inhibitors have significantly improved the outcomes of patients with advanced melanoma.1 In particular, use of BRAF and MEK inhibitors generally results in higher objective response rates for patients with BRAF V600E-mutant disease, whereas immune checkpoint inhibitors typically result in more durable responses. Importantly, these treatments have distinct mechanisms of action; thus, it has long been hypothesized that combining immune checkpoint inhibitors with BRAF and MEK inhibitors may result in a higher frequency of durable responses.2,3 Evidence from previous preclinical modeling and analysis of patient biopsy specimens suggest that inhibition of the BRAF V600E driver oncoprotein facilitates an antitumor immune response.4–7

Results of early clinical trials in patients with previously untreated metastatic BRAF V600E-mutant melanoma highlight the promise of this strategy. For example, 15 patients were treated with the anti-PD-1 antibody pembrolizumab plus the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib in the phase 1 portion of the KEYNOTE-022 study,8 and 39 patients received the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib in combination with the anti-PD ligand 1 (PD-L1) antibody atezolizumab in another phase 1 trial.9 Efficacy data obtained from these two studies were remarkably consistent,
with the combination of BRAF, MEK, and immune checkpoint inhibitors producing objective response rates of 73% and 72%, respectively; median progression-free survival was 15.4 months and 12.9 months, respectively. Interestingly, tumor biopsy specimens showed increased tumor infiltration of CD8+ T cells and expression of PD-L1.8

In the latter study, the objective response rate was 75% (n=27), the complete response rate was 33% (n=12), and the 12 month progression-free survival rate was 63.3%.11

In addition, the randomized, double-blind, phase 2 part of KEYNOTE-022 compared the efficacy of the triplet combination of pembrolizumab, dabrafenib, and trametinib with the efficacy of the doublet combination of placebo with dabrafenib and trametinib.12 At a median follow-up of 9.6 months, although the primary endpoint of progression-free survival did not show statistically significant improvement in the triplet arm compared with the doublet arm, numerically higher values were observed (16.0 months vs 10.3 months; HR, 0.66; p=0.043). After additional follow-up of a median 36.6 months, we report mature results showing clinically substantial improvement in duration of response and survival.

**METHODS**

**Study design**

KEYNOTE-022 was a five-part, multicenter, phase 1/2 dose-finding and preliminary efficacy study of pembrolizumab plus dabrafenib and trametinib in patients with unresectable or metastatic melanoma or solid tumors (parts 4 and 5 only) (online supplemental table S1). Part 3 was the randomized, double-blind, phase 2 portion in which patients with previously untreated advanced melanoma were randomly assigned 1:1 to receive pembrolizumab or placebo combined with dabrafenib and trametinib. Patients were enrolled from 22 medical centers in seven countries.12

**Patients**

Eligible patients were aged ≥18 years and had unresectable stage III or stage IV cutaneous melanoma, with at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST V1.1) on imaging (CT or MRI). Patients were required to have BRAF-mutation positive (V600E or V600K) disease should not have previously received systemic therapy for advanced melanoma, and should not present with active central nervous system metastases and/or carcinomatous meningitis.

**Procedures**

Patients were randomly assigned to receive pembrolizumab plus dabrafenib and trametinib or placebo plus dabrafenib and trametinib using an interactive voice response system/integrated web response system. Randomization was stratified by Eastern Cooperative Oncology Group performance status (ECOG PS; 0 vs 1) and lactate dehydrogenase level (≥1.1× upper limit of normal (ULN) vs ≤1.1× ULN). Because of the low number of patients, the ECOG PS 1 and lactate dehydrogenase level >1.1× ULN strata were combined.

Patients received pembrolizumab 2 mg/kg or placebo intravenously every 3 weeks combined with dabrafenib 150 mg orally two times per day and trametinib 2 mg orally one time a day. Treatment was continued for up to 24 months or until disease progression, unacceptable toxicity, or withdrawal from the study. Trametinib and/or dabrafenib treatment could be continued beyond 24 months per standard of care until disease progression. Dose modification or interruption of pembrolizumab, placebo, trametinib, or dabrafenib was allowed to manage toxicity per protocol-specified management guidelines.12

Response and disease progression were assessed radiologically per RECIST V1.1 by investigator review. Tumor imaging was performed at baseline, at 12 weeks after the first study treatment, every 6 weeks following this up to 18 months, and every 12 weeks thereafter while the patient remained on study therapy. Patients were monitored throughout the study for adverse events, which were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (V.4.0). Immune-mediated adverse events are defined in the online supplemental. PD-L1 expression in tumor samples was determined using the PD-L1 IHC 22C3 pharmDx assay (Agilent Technologies).

**Outcomes**

The primary endpoint was progression-free survival, defined as the time from randomization to the first documented disease progression or death from any cause, whichever occurred first. Secondary endpoints were objective response rate, duration of response, and overall survival.

**Statistical analysis**

Progression-free survival, objective response rate, and overall survival were assessed in the intention-to-treat population. Safety was assessed in patients who received at least one dose of study drug. Clinical data were collected using InForm V.4.6.5 software (Oracle Health Sciences, Redwood City, California, USA), and SAS V.9.4 software (SAS Institute, Cary, North Carolina, USA) was used for all statistical analyses. Progression-free survival was estimated using the Kaplan-Meier method with patients censored at the last disease assessment date or at the last disease assessment before initiation of a new anticancer treatment. A stratified log-rank test was used to assess between-group differences in progression-free survival. A Cox proportional hazards model with Efron’s method of tie-handling was used to estimate HRs and 95% CIs. The Kaplan-Meier
method was used for summary statistics for duration of response and overall survival (see protocol for censoring rules). The treatment comparison for objective response rate was based on Miettinen and Nurminen’s method. Assuming an HR of 0.5, the study needed approximately 74 progression-free survival events to have 80% power to reject the null hypothesis at a one-sided 0.025 type I error. The observed HR had to be approximately 0.62 or lower for the treatment effect to be statistically significant. The primary analysis was conducted using all available alphas; therefore, this subsequent post hoc analysis cannot be considered to carry any statistical significance. The study was overseen by a data monitoring committee and is registered at ClinicalTrials.gov (NCT02130466).

RESULTS
Between November 30, 2015 and April 24, 2017, 180 patients were screened for eligibility and 120 were randomly assigned to receive pembrolizumab plus dabrafenib and trametinib (doublet therapy; n=60 (50%)) or placebo plus dabrafenib and trametinib (doublet therapy; n=60 (50%)) (online supplemental figure S1). All patients received at least one dose of study treatment.

The median age was 56 years (range, 18–83), and 58% (n=69) of patients were men. Baseline characteristics were generally well balanced between arms, apart from a higher proportion of patients with M1c disease in the triplet arm (82% (n=49) triplet arm, 63% (n=38) doublet arm) (online supplemental table S2). The median exposure duration for each study drug is provided in online supplemental table S3.

At data cut-off (June 26, 2019), the median time from randomization to data cut-off was 36.6 months (range, 26.1–42.9) in the triplet arm and 36.4 months (range, 27.2–41.6) in the doublet arm. Fifteen patients (13%) were receiving treatment: 11 (18%) in the triplet arm and 4 (7%) in the doublet arm. Forty-three patients (72%) had discontinued treatment in the triplet arm and 56 (93%) in the doublet arm, mainly because of adverse events (18 (30%) triplet arm, 10 (17%) doublet arm) and progressive disease (17 (28%) triplet arm, 4 (73%) doublet arm).

Thirty-four patients (57%) in the triplet arm and 53 (88%) in the doublet arm had a progression event. Median progression-free survival was 16.9 months (95% CI 11.3 to 27.9) in the triplet arm and 10.7 months (95% CI 7.2 to 16.8) in the doublet arm (HR 0.53; 95% CI 0.34 to 0.83) (figure 1A). The 12-month progression-free survival rates were 62% (95% CI 48.1% to 73.5%) in the triplet arm and 47% (95% CI 33.4% to 58.7%) in the doublet arm, and the 24-month progression-free survival rates were 41% (95% CI 27.4% to 54.2%) and 16% (95% CI 8.1% to 27.1%), respectively.

Exploratory subgroup analysis of progression-free survival showed that the HRs for the subgroups favored the triplet over the doublet arm in patients who were aged ≤65 years, men, had ECOG PS 0, or had elevated lactate dehydrogenase levels (online supplemental figure S2). Twenty-six patients (43%) in the triplet arm and 36 (60%) in the doublet arm died. Median overall survival was not reached in the triplet arm and was 26.3 months in the doublet arm (HR, 0.64; 95% CI 0.38 to 1.06) (figure 1B). The 12-month overall survival rates were 80% (95% CI 67.5% to 88.1%) in the triplet arm and 73% (95% CI 60.2% to 82.7%) in the doublet arm, and the 24-month overall survival rates were 63% (95% CI 49.4% to 73.9%) and 52% (95% CI 38.4% to 63.4%), respectively. Exploratory subgroup analysis of overall survival...
showed no difference between the triplet and doublet arms in any subgroup (online supplemental figure S3).

The objective response rate was 63% in the triplet arm and 72% in the doublet arm (difference in rate −8.5%; 95% CI −24.8 to 8.3). A complete response was reported in 12 patients (20%) in the triplet arm and 9 patients (15%) in the doublet arm (table 1). The median duration of response was 25.1 months in the triplet arm and 12.1 months in the doublet arm (HR, 0.32; 95% CI 0.17 to 0.59) (figure 2). At the data cut-off, responses were ongoing in 11 of 38 patients (29%) in the triplet arm and 4 of 43 patients (9%) in the doublet arm (online supplemental figure S4).

Grade 3–5 adverse events occurred in 42 patients (70%) in the triplet arm and 27 patients (45%) in the doublet arm; grade 3–5 treatment-related adverse events were reported in 35 patients (58%) and 15 patients (25%), respectively. Adverse events led to dose reductions in 16 patients (27%) and 9 patients (15%). Adverse events leading to dose interruption occurred in 50 patients (83%) and 41 patients (68%), respectively; the most common were fever (55%; n=33) and diarrhea (15%; n=9) in the triplet arm and fever (45%; n=27) and neutropenia (10%; n=6) in the doublet arm. Adverse events led to treatment discontinuation in 28 patients (47%) in the triplet arm and 12 patients (20%) in the doublet arm (online supplemental table S4). Treatment-related adverse events occurred in 57 patients (95%) in the triplet arm and 56 patients (93%) in the doublet arm (table 2); the most common were fever (72%; n=43), rash (37%; n=22), and chills (35%; n=21) in the triplet arm and fever (68%; n=41), chills (38%; n=23), and fatigue (38%; n=23) in the doublet arm. Immune-mediated adverse events occurred in 31 patients (52%) in the triplet arm and 9 patients (15%) in the doublet arm (table 3); the most frequently occurring in the triplet arm were pneumonitis (17%; n=10) and hypothyroidism (8%; n=5). Serious treatment-related adverse events occurred in 24 patients (40%) and 14 patients (23%), respectively. One patient (1.7%) in the triplet arm died of treatment-related pneumonitis.

**DISCUSSION**

In our previous report on part 3 of the KEYNOTE-022 trial,12 despite a median progression-free survival of
16.0 months in the triplet arm versus 10.3 months in the doublet arm and an HR of 0.66, the study did not meet the prespecified primary endpoint of progression-free survival. Analysis was performed after 9.5 months of follow-up at the occurrence of 72 progression-free survival events; the study plan required 74 events to have 80% power to reject the null hypothesis. The short follow-up time could have influenced the results.

Although the current analysis was not protocol-specified, as data matured with a longer median follow-up of 36.6 months, improvements in progression-free survival (16.9 months and 10.7 months, respectively), differences in duration of response (25.1 months and 12.1 months, respectively), and overall survival (not reached and 26.3 months, respectively) became more pronounced between the two arms.

Patients in the doublet arm had a higher initial objective response rate than patients in the triplet arm at the time of the primary analysis, which was considered to have been likely due to an imbalance in the baseline prognostic factors between the treatment arms (more patients in the triplet arm had M1c disease). This result persisted in the mature analysis, even though the survival benefit became more pronounced in the triplet arm. Although it is unclear whether other factors may have contributed to this dichotomy, the additional follow-up in the patients in the triplet arm showed deeper and more durable responses than in the doublet arm and a higher rate of complete responses, a lower rate of relapses, and progressive separation in the curves of duration of response. Improved depth of response was associated with improved survival in pooled analyses of trials in melanoma; therefore, it is likely that these response characteristics resulted in the further separation of the progression-free survival and overall survival curves. These data confirm the rationale of the study and are also consistent with the notion that adding anti-PD-1 blocking antibodies to BRAF plus MEK inhibitor therapy may not improve the initial objective response rates but instead prevent or delay the onset of acquired resistance, as demonstrated by the progressive separation of the time-to-event curves.

Table 2 Treatment-related adverse events occurring in ≥15% of patients in either treatment arm (all-subjects-as-treated population)

| Event, n (%)                      | Pembrolizumab + dabrafenib + trametinib n=60 | Placebo + dabrafenib + trametinib n=60 |
|-----------------------------------|-----------------------------------------------|----------------------------------------|
|                                   | Any grade                                     | Grade 3–5*                              |
|                                   | Any grade                                     | Grade 3–5*                              |
| Any event                         | 57 (95.0)                                     | 56 (93.3)                               |
|                                   | 35 (58.3)                                     | 15 (25.0)                               |
| Gastrointestinal disorders        |                                               |                                        |
| Diarrhea                          | 17 (28.3)                                     | 7 (11.7)                                |
|                                   | 2 (3.3)                                       | 0 (0.0)                                 |
| Nausea                            | 16 (26.7)                                     | 18 (30.0)                               |
|                                   | 0 (0.0)                                       | 0 (0.0)                                 |
| Vomiting                          | 12 (20.0)                                     | 11 (18.3)                               |
|                                   | 0 (0.0)                                       | 0 (0.0)                                 |
| General disorders and administration site conditions |                                               |                                        |
| Asthenia                          | 15 (25.0)                                     | 7 (11.7)                                |
|                                   | 0 (0.0)                                       | 2 (3.3)                                 |
| Chills                            | 21 (35.0)                                     | 23 (38.3)                               |
|                                   | 0 (0.0)                                       | 1 (1.7)                                 |
| Fatigue                           | 16 (26.7)                                     | 23 (38.3)                               |
|                                   | 1 (1.7)                                       | 0 (0.0)                                 |
| Fever                             | 43 (71.7)                                     | 41 (68.3)                               |
|                                   | 6 (10.0)                                      | 2 (3.3)                                 |
| Investigations                    |                                               |                                        |
| ALT increased                     | 12 (20.0)                                     | 10 (16.7)                               |
|                                   | 2 (3.3)                                       | 2 (3.3)                                 |
| AST increased                     | 12 (20.0)                                     | 12 (20.0)                               |
|                                   | 4 (6.7)                                       | 2 (3.3)                                 |
| Blood ALP                         | 8 (13.3)                                      | 11 (18.3)                               |
|                                   | 1 (1.7)                                       | 1 (1.7)                                 |
| GGT increased                     | 5 (8.3)                                       | 9 (15.0)                                |
|                                   | 4 (6.7)                                       | 3 (5.0)                                 |
| Musculoskeletal and connective tissue disorders |                                               |                                        |
| Arthralgia                        | 18 (30.0)                                     | 12 (20.0)                               |
|                                   | 2 (3.3)                                       | 0 (0.0)                                 |
| Myalgia                           | 10 (16.7)                                     | 9 (15.0)                                |
|                                   | 0 (0.0)                                       | 1 (1.7)                                 |
| Skin and subcutaneous tissue disorders |                                               |                                        |
| Dermatitis acneiform              | 9 (15.0)                                      | 4 (6.7)                                 |
|                                   | 0 (0.0)                                       | 0 (0.0)                                 |
| Pruritus                          | 9 (15.0)                                      | 6 (10.0)                                |
|                                   | 0 (0.0)                                       | 0 (0.0)                                 |
| Rash                              | 22 (36.7)                                     | 16 (26.7)                               |
|                                   | 3 (5.0)                                       | 0 (0.0)                                 |
| Vitiilgo                          | 12 (20.0)                                     | 0 (0.0)                                 |
|                                   | 0 (0.0)                                       | 0 (0.0)                                 |

*One patient in the triplet arm had grade 5 treatment-related pneumonitis.

ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase.
advantage of triplet versus doublet therapy in all patient subgroups, particularly in patients younger than 65 years of age, male patients, and patients with elevated lactate dehydrogenase levels at baseline. Patients with elevated lactate dehydrogenase levels have adverse features for durable response with dabrafenib and trametinib or anti-PD-1 therapy alone, have worse prognosis, and are at higher risk for early progression with immune or targeted therapies. Our findings support the idea that these patients can be offered triplet combination therapy to circumvent the development of resistance.

Although the use of BRAF and MEK inhibitors is recommended for patients with BRAF-mutant disease, immune checkpoint inhibitor combinations have also been shown to be effective in this population. In the CheckMate 067 trial, nivolumab plus ipilimumab (5-year overall survival rate, 60%) or nivolumab alone (46%) improved long-term survival compared with ipilimumab (30%) in patients with previously untreated BRAF-mutant melanoma. The 5-year progression-free survival rate in CheckMate 067 was 38% with nivolumab plus ipilimumab, 22% with nivolumab alone, and 11% with ipilimumab in patients with previously untreated BRAF-mutant melanoma. Notably, 24-month overall survival and progression-free survival rates with nivolumab plus ipilimumab are similar to those with triplet therapy in the current analysis (63% and 41%, respectively). Robust antitumor activity has also been observed with pembrolizumab plus reduced-dose ipilimumab in the phase 1b KEYNOTE-029 study of patients with BRAF-mutant melanoma in which the majority (87%) of patients had not received prior systemic therapy. Patients with BRAF-mutant melanoma who had not previously received BRAF or MEK inhibitor therapy had a response rate of 60%, whereas those who had previously received BRAF or MEK inhibitor therapy had a response rate of 38%. While the results of these studies suggest that patients with BRAF-mutant melanoma may benefit from immune checkpoint inhibitor combinations, it remains unknown how such regimens compare with targeted therapies, or indeed with the triplet therapy investigated in the current analysis, as cross-trial comparisons are hindered by differences in study design and patient population. Trials directly comparing these therapeutic combinations are required to definitively ascertain which regimen is more effective in patients with BRAF-mutant melanoma. Meanwhile, several clinical trials currently underway are investigating the optimal sequencing of targeted and immune checkpoint inhibitor therapy, including COWBOY (NCT02968303), Immuno-CobiVem (NCT02902029), and EBIIN (NCT03235245); the results of these should provide insight into which regimen is more effective as front-line therapy.

In the current analysis, the triplet combination was associated with greater toxicity compared with the doublet regimen. Patients who received pembrolizumab plus dabrafenib and trametinib experienced a higher rate of grades 3–5 treatment-related adverse events than patients who received placebo plus dabrafenib and trametinib (58% vs 25%), leading to a higher discontinuation rate because of toxicity. Both immune-mediated adverse events (52% vs 15%) and serious treatment-related adverse events (40% vs 23%) were also more common in the triplet arm compared with the doublet arm. Interestingly, discontinuation resulted primarily from disease progression (44 patients (73%)) in the doublet arm but from adverse events (18 patients (30%)) in the triplet arm. Studies are ongoing to address whether different intermittent or dose-sequencing regimens, combining immunotherapies with targeted therapies for melanoma, may be able to maintain the benefit of the concomitant triplet therapy while reducing toxicity (NCT02858921, NCT02224781, and NCT02631447 (Sequential COMBo Immuno and Targeted therapy)).

Recently, positive data were reported from the phase 3 IMSpire 150 trial comparing the frontline use of atezolizumab plus vemurafenib and cobimetinib with that of vemurafenib and cobimetinib alone in patients with BRAF\textsuperscript{V600E}-mutation-positive-advanced melanoma. This study reported a significant improvement in progression-free survival with the combination of atezolizumab, vemurafenib, and cobimetinib versus vemurafenib and cobimetinib alone (15.1 vs 10.6 months) and a 2-year overall survival rate of 60% vs 53%, respectively; progression-free survival and overall survival rates were similar to those observed in the current analysis. While

---

**Table 3** Immune-mediated adverse events\(^\text{a}\) occurring in at least one patient in either treatment arm (all-subjects-as-treated population)

| Event, n (%) | Pembrolizumab + dabrafenib + trametinib n=60 | Placebo + dabrafenib + trametinib n=60 |
|-------------|---------------------------------------------|----------------------------------------|
| At least one immune-mediated adverse event | 31 (51.7) | 9 (15.0) |
| Pneumonitis | 10 (16.7) | 2 (3.3) |
| Hypothyroidism | 5 (8.3) | 1 (1.7) |
| Severe skin reactions | 5 (8.3) | 1 (1.7) |
| Hepatitis\(^1\) | 4 (6.7) | 2 (3.3) |
| Hyperthyroidism | 3 (5.0) | 0 (0.0) |
| Uveitis | 3 (5.0) | 2 (3.3) |
| Colitis | 2 (3.3) | 1 (1.7) |
| Hypophysitis | 2 (3.3) | 0 (0.0) |
| Nephritis | 2 (3.3) | 0 (0.0) |
| Infusion reactions | 1 (1.7) | 1 (1.7) |
| Myositis | 0 (0.0) | 1 (1.7) |

\(^{a}\)Immune-mediated adverse events were selected from a prespecified list and defined as events of unknown cause associated with drug exposure and consistent with an immune event.

\(^{1}\)Includes autoimmune hepatitis, drug-induced liver injury, and hepatitis.
the lead-in of targeted therapies before initiating atezolizumab in the IMspire150 trial could have affected the early efficacy results, it seems not to have influenced toxicity. In fact, the incidence of grade 3/4 treatment-related adverse events in IMspire 150 was substantially higher than in the current analysis (atezolizumab, vemurafenib, and cobimetinib arm, 79%; vemurafenib and cobimetinib arm, 73%). In contrast, a recent analysis of part 3 of the COMBI trial reported that spartalizumab plus dabrafenib and trametinib did not significantly improve progression-free survival compared with placebo plus dabrafenib and trametinib among patients with previously untreated \( \text{BRAF}^{V600E} \)-mutant melanoma.\(^{26}\) In the COMBI study, the median progression-free survival was 16.2 months for spartalizumab plus dabrafenib and trametinib versus 12.0 months for placebo plus dabrafenib and trametinib (HR, 0.82; 95% CI 0.655 to 1.027).\(^{26}\) Median overall survival was not reached in either arm, with analyses ongoing. Grade 3 or higher treatment-related adverse events were reported in 55% of patients receiving spartalizumab plus dabrafenib and trametinib compared with 33% of patients receiving placebo plus dabrafenib and trametinib. Although the results of these studies provide insight into the role of the combination of PD-1/PD-L1 inhibitors with BRAF and MEK inhibitors in patients with advanced, treatment-naive \( \text{BRAF}^{V600E} \)-mutant melanoma, differences in agents investigated, study design, and patient population preclude direct comparison. In conclusion, pembrolizumab plus dabrafenib and trametinib as first-line therapy in patients with advanced \( \text{BRAF}^{V600E} \)-mutant melanoma provided a clinically substantial improvement in progression-free survival, longer duration of response, and higher overall survival rate compared with placebo plus dabrafenib and trametinib. An important lesson from this analysis is the further improvement in outcomes observed with longer follow-up. However, the results should be interpreted with caution given the post hoc nature of the analysis. This finding should be considered in the design of future studies evaluating immunotherapy combinations, as duration of response may be a critical factor. Indeed, durable responses can allow the differences between treatments to become more pronounced over time, and an early data cut-off may not provide the full picture of the true clinical benefit.\(^{27}\)

**Author affiliations**

1 Cancer Biotherapy Unit, Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy
2 Center for Immuno-Oncology, University Hospital of Siena; University of Siena, Siena, Italy
3 Unit of Melanoma Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
4 University of Queensland, and Gallipoli Medical Research Foundation, Greenslopes Private Hospital, Woolloongabba, Queensland, Australia
5 Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
6 Division of Oncology, Sheba Medical Centre, Tel HaShomer Hospital, Tel Aviv, Israel
7 IE0 European Institute of Oncology IRCCS, Milan, Italy
8 Ospedale Policlinico San Martino IRCCS, Genoa, Italy
9 Melanoma Institute Australia, The University of Sydney, and Royal North Shore Hospital, Sydney, New South Wales, Australia
10 Department of Medical Oncology and Translational Research, Mater Hospital, North Sydney, New South Wales, Australia
11 Medical Oncology, Auckland City Hospital, Auckland, New Zealand
12 Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
13 Sharette Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
14 Rambam Health Care, Haifa, Israel
15 Global Drug Development, Oncology, Novartis, East Hanover, New Jersey, USA
16 Department of Clinical Oncology, Merck & Co Inc, Kenilworth, New Jersey, USA
17 Department of Medicine, University of California Los Angeles and the Jonsson Comprehensive Cancer Center, Los Angeles, California, USA
18 Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione “G. Pascale”, Naples, Italy

**Correction notice** This article has been corrected since it was first published. Dr. Queirolo’s affiliations have been updated.

**Twitter** Paolo Antonio Ascieto @PAscierto

**Acknowledgements** The authors thank the patients and their families and the investigators and site personnel. They also thank the following employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA: Scott Ebbinghaus, Nageafite Ibrahim, Blanca Horom Moreno, Melina Leibi, Maureen Bucci, Jesse Siegel, Diana Furewicz, Karen Favata, Nadine Cole, James Anderson, and Rahul Yadav Badulla. Editorial assistance in preparation of this report was provided by Jemimah Walker, PhD, and Doyel Mitra, PhD, CMPP, of ApolloCom, Yardley, PA, and was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Contributors named in this report gave their permission to be acknowledged for their contributions.

**Collaborators** Antoni Ribas, Sachin Agarwal, Charles Cowey, Wilson Miller, Teresa Petrella, Felix Couture, Paolo Ascieto, Michele Del Vecchio, Michele Maio, Francesco Spagnolo, Pier Francesco Ferrucci, Jacob Schachter, Michael Lotem, Karen Drumea, Eva Ellebaek, Inge Marie Svane, Lars Bahrhold, Henrik Schmitt, Victoria Atkinson, Georgina V. Long, Matteo Carlini, Michael McCrystal

**Contributors** GVL, SJD, and AR were involved in the conception, design, or planning of the study. PFF, AMDG, MDV, VA, JS, PO, GVL, RS, IMS, ML, ESC, MA-A, and AR acquired data for the study. PFF, MDV, VA, PO, GVL, IMS, RG, ESC, AR, and PAA analyzed the data. PFF, AMDG, MDV, VA, HS, JS, PO, GVL, EG, RG, SJD, ESC, AR, and PAA interpreted the results. PFF, MDV, VA, EG, AR, and PAA drafted the manuscript with contribution from all authors. PFF, AMDG, MDV, VA, HS, JS, PO, GVL, RS, IMS, EG, RS, SJD, ESC, MA-A, AR, and PAA critically reviewed or revised the manuscript for important intellectual content. MDV also contributed to the provision of study materials and patient data. All authors reviewed the interim drafts and the final version of the manuscript and agree with its content and submission. All authors had access to all the relevant study data and related analyses and vouch for the completeness and accuracy of the presented data.

**Funding** Funding for this research was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Study drug was provided by Novartis and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

**Competing interests** PFF has received personal fees from Novartis, Roche, Bristol-Myers Squibb, Pierre Fabre, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Kenilworth, New Jersey, USA (MSD). AMDG reports other from MSD during the conduct of the study; reports other from Incyte, GlaxoSmithKline, Pierre Fabre, and Sanofi outside the submitted work; and has served as an advisor and consultant for MSD, Incyte, GlaxoSmithKline, Pierre Fabre, and Sanofi. MDV has received personal fees from Novartis, MSD, and BMS outside the submitted work and has served as an advisor and consultant for MSD, BMS, Novartis, Pierre Fabre and Sanofi. VA has received personal fees and travel support from Bristol-Myers Squibb; personal fees from MSD, Merck Serono, Novartis, Pierre Fabre, Roche and Nektar; and travel support from OncoSec Medical, during the conduct of the study. HS received a research grant and personal fees from MSD and has received personal fees from Bristol-Myers Squibb, Incyte, Novartis, and Pierre Fabre outside the submitted work. PD has received personal fees from Roche, Novartis, Bristol-Myers Squibb, MSD, Sanofi, and Pierre Fabre. GVL is consultant advisor for Aduro Biotech Inc, Amgen Inc, Array Biopharma inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Highlight Therapeutics S.L., MSD, Novartis Pharma AG, Pierre Fabre, QBiotics Group Limited, Regeneron Pharmaceuticals Inc, SkylineDx B.V. RS reports personal fees from MSD New Zealand, outside the submitted work. IMS reports other (trial expenses) from MSD. IMS has received other funds from MSD during the conduct of the study. EG is an employee and stockholder...
REFERENCES

1 Luke JJ, Flaherty KT, Ribas A, et al. Targeted agents and immunotherapies: optimizing outcomes in melanoma. *Nat Rev Clin Oncol* 2017;14:463–82.

2 Beegle J, Ribas A. Targeted therapies to improve tumor immunotherapy. *Clin Cancer Res* 2008;14:4385–91.

3 Pelster MS, Amaria RN. Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials. *Ther Adv Med Oncol* 2011;11:1758885911830826.

4 Willmort JS, Long GV, Howie JR, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. *Clin Cancer Res* 2012;18:1386–94.

5 Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. *Clin Cancer Res* 2013;19:1225–31.

6 Hu-Lieskovszky S, Ma S, Hometen Moreno B, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. *Sci Transl Med* 2015;7:279ra41–79.

7 Deken MA, Gadiot J, Jordanova ES, et al. Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. *Oncogene* 2020;39:12385–557.

8 Ribas A, Lawance D, Atkinson V, et al. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. *Nat Med* 2019;25:936–40.

9 Sullivan RJ, Hamid O, Gonzalez R, et al. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. *Nat Med* 2019;25:929–35.

10 Ribas A, Butler M, Lutzky J, et al. Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. *J Clin Oncol* 2015;33:3003–03.

11 Long GV, Lebbe C, Atkinson V, et al. The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i. *J Clin Oncol* 2019;37:9531–31.

12 Ascierto PA, Ferrucci PF, Fisher R, et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. *Nat Med* 2019;25:941–6.

13 Eisenhauer EA, Therasse P, Bogarts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* 2009;45:228–47.

14 Miettinen O, Nurminen M. Comparative analysis of two rates. *Stat Med* 1985;4:213–26.

15 Lewis KD, Larkin J, Ribas A, et al. Impact of depth of response on survival in patients treated with cobimetinib + vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. *Br J Cancer* 2019;121:522–30.

16 Osgood C, Mulkey F, Mishra-Kalyani PS, et al. FDA analysis of depth of response (DoR) and survival across 10 randomized controlled trials in patients with previously untreated unresectable or metastatic melanoma (UMM) by therapy type. *J Clin Oncol* 2019;37:9506–08.

17 Chen T-T. Statistical issues and challenges in immuno-oncology. *J Immunother Cancer* 2013;1:18.

18 Thörén FB, Anderson H, Strannégard Örjan. Late divergence of survival curves in cancer immunotherapy trials: interpretation and implications. *Cancer Immunol Immunother* 2013;62:1547–51.

19 Robert C, Grob JJ, Stroyakovskiy D, et al. Five-Outcome analyses with dabrafenib plus trametinib in metastatic melanoma. *N Engl J Med* 2019;381:626–36.

20 Schadendorf D, Long GV, Stromovskiy D, et al. Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. *Eur J Cancer* 2017;82:45–55.

21 Weide B, Martens A, Hassel JC, et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. *Clin Cancer Res* 2016;22:487–96.

22 National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. *Cutaneous Melanoma*. Version 4.2020 Plymouth Meeting, PA: National Comprehensive Cancer Network, 2020.

23 Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. *N Engl J Med* 2019;381:1535–46.

24 Long GV, Atkinson V, Cebon JS, et al. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. *Lancet Oncol* 2017;18:1292–10.

25 Gutzmmer R, Stroyakovskiy D, Gogas H, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF-V600-mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2020;21:1835–44.

26 Nathan P, Dummer R, Long GV, et al. Spatacluzumab plus dabrafenib and trametinib (Sparta Dam-Track) in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial. *Nat Oncol* 2020;21:1146–215.

27 Ascierto PA, Long GV. Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials. *Lancet Oncol* 2017;16:1037–9.
Correction: KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

Ferrucci PF, Di Giacomo AM, Del Vecchio M for the KEYNOTE-022 international team, et al. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. J Immunother Cancer 2020;8:e001806. doi: 10.1136/jitc-2020-001806

This article has been corrected since it was first published. Dr. Queirolo’s affiliations have been updated to the following: ‘IEO European Institute of Oncology IRCCS, Milan, Italy’ and ‘Ospedale Policlinico San Martino IRCCS, Genoa, Italy’.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

J Immunother Cancer 2021;9:e001806corr1. doi:10.1136/jitc-2020-001806corr1